Latest filing published 06 Apr 2026 for Agios Pharmaceuticals, INC.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
James William Burns, listed as senior executive, appears in our data through filings on Agios Pharmaceuticals, Inc. shares, published by SEC (Form 4). Between 10 February 2022 and 2 April 2026, the trades on record add up to 38 filings.
The open-market record consists of 14 sales worth €1.7M, with no purchase. Other entries cover 1 share grant and 23 option exercises. In 2026 alone, the filings show no purchases and 5 sales.
The record was last updated on 6 April 2026 with an open-market sale (€99k) in Agios Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 38 declarations